Stanford inventors have developed a method of using CRISPR/Cas9 or similar gene editing technologies to genetically edit an individual's own myeloid cells for specific gene targets, which are critical to wound repair, and applying these edited cells in a hydrogel to promote ra
Researchers in Prof. David Myung's laboratory have developed a bio-compatible, crosslinking gel that can be used for in situ repair of damaged cornea or as a three-dimensional scaffold for keratocyte-keratinocyte tissue culture.
Using their newly developed acetyl-click screening platform, researchers at Stanford have identified riboflavin analogs as small molecule inhibitors of Histone Acetyltransferase 1 (HAT1) with anti-cancer activity.
Stanford researchers in the Mahajan Lab have created a customizable proteomics platform that can identify protein biomarkers to differentiate among ischemic eye diseases and identify novel therapeutic targets to treat them.
Stanford researchers have designed and prototyped an inexpensive, compact and easy-to-use smartphone lens mount for the capture of high quality photographs and videos of the eye's front and back structures.
Researchers at Stanford University and Johns Hopkins University have identified an antibody that is negatively associated with cancer in patients diagnosed with dermatomyositis.
Engineered viruses have great potential as cancer treatments. However, the only currently approved viral therapy, T-vec (Talimogene laherparepvec), suffers from off-target effects that limit its use to intratumoral injection.
Researchers at Stanford have developed a rapid and efficient method for high-throughput genome editing using CRISPR/Cas9. The CRISPR/Cas9 system allows researchers to edit any site in an organism's genome.